Sana Biotechnology

Historical price data

Sana Biotechnology aims to create and deliver engineered cells as medicines to address the root causes of disease. The company has established two complementary, proprietary technology platforms designed to overcome the major hurdles of immune rejection and targeted in vivo delivery that have limited the field. Its strategy focuses on advancing a pipeline of potentially curative therapies for type 1 diabetes and B-cell malignancies, with its most advanced programs now entering early clinical testing. Despite being pre-revenue, Sana has assembled a seasoned leadership team and secured significant capital to pursue its ambitious vision.

Two complementary platforms: 1) Ex Vivo Hypoimmune Platform to create universal, off-the-shelf cell therapies by eliminating immune rejection signals; 2) In Vivo Fusogen Platform for targeted delivery of genetic payloads to specific cells within the body.

In type 1 diabetes, Sana competes with Vertex and CRISPR Therapeutics, differentiating with its Hypoimmune platform designed to avoid immunosuppression. In cell therapy, it faces numerous companies developing allogeneic and in vivo CAR-Ts, where success will hinge on demonstrating superior efficacy, safety, or convenience.